# Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

> **NCT01213888** · NA · TERMINATED · sponsor: **University of British Columbia** · enrollment: 3 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Trientine Hydrochloride
- **DRUG:** Oral placebo capsules

## Key facts

- **NCT ID:** NCT01213888
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low enrollment \& superior treatments available for diabetic macular edema including anti-VEFG therapies such as bevacizumab and ranibizumab.
- **Last updated:** 2013-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213888, "Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01213888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*